NCT03319459 2021-11-22FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid TumorsFate TherapeuticsPhase 1 Completed44 enrolled
NCT04464967 2021-05-12Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR CancersNKGen Biotech, Inc.Phase 1/2 Withdrawn
NCT00622674 2017-12-02Bortezomib and Cetuximab in Treating Patients With Advanced Solid TumorsMasonic Cancer Center, University of MinnesotaPhase 1 Completed37 enrolled
NCT00101348 2014-06-11Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1/2 Completed66 enrolled